Amgen Biosimilar And EYLEA Patent Dispute
Amgen gets early win in Regeneron lawsuit over Eylea biosimilar
Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a federal judge in West Virginia said on Monday.
Regeneron's stock drops as it loses bid to block Amgen's Eylea biosimilar
Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for blockbuster eye disease drug Eylea, the same judge has rejected the company’s attempt to block Amgen’s Eylea biosimilar.
Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors
Regeneron Pharmaceuticals is a leading biotech firm with a strong portfolio. Click here to know what justifies a Buy rating for REGN stock.
Regeneron’s Eylea biosimilar fight heats up
Shares of Regeneron fell 5% yesterday after the company’s effort to block Amgen from launching a biosimilar version of its blockbuster eye drug Eylea hit a legal roadblock.
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
Shares of Regeneron Pharmaceuticals, Inc. REGN were down 4.63% after an unfavorable ruling in its lawsuit against Amgen AMGN in the United States District Court for the Northern District of West Virginia.
Regeneron falls after judge denies injunction blocking Amgen Eylea biosimilar (update)
Adds Wells Fargo analyst comment. Regeneron Pharmaceuticals (NASDAQ:REGN) quickly dropped 3.5% after a judge denied the company's motion for a preliminary injunction to block an Amgen (AMGN) biosimilar version of Regeneron's blockbuster Eylea drug.
Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): ‘Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Bio…
Stocks to Watch. In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands ...
Regeneron: Long-Term Defensive Investment
Regeneron's R&D expenses are projected to reach $5 billion, but the business remains highly profitable. Read why I rate REGN ...
Regeneron buys Quad’s 1.1-million-square-foot plant in Saratoga Springs
Regeneron Pharmaceuticals has purchased Quad’s shuttered printing plant in Saratoga Springs, sparking hopes for economic ...
Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling
Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...
STAT5d
Pharmalittle: We’re reading about a Regeneron biosimilar fight, a ‘positive surprise’ for Biogen lupus drug, and more
A U.S. judge ruled that Regeneron Pharmaceuticals cannot immediately block U.S. sales of a proposed copy of its blockbuster ...
Medscape9d
Two New Drugs Approved for Age-Related Macular Degeneration
The European Medicines Agency approved Afqlir and Opuviz to treat age-related macular degeneration while reiterating its ...
Regeneron Pharmaceuticals Suffers Worst Month in Two Years After Legal Setback
Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...